Association between TNFRSF11B gene polymorphisms and history of ischemic stroke in Italian diabetic patients

Human Genetics

Volumn 132, Issue 1, 2013, Pages 49-55

  Biscetti, Federico ^a,b   Straface, Giuseppe ^c   Giovannini, Silvia ^a   Santoliquido, Angelo ^d   Angelini, Flavia ^b   Santoro, Luca ^d   Porreca, Carlo Filippo ^a,b   Pecorini, Giovanni ^a,b   Ghirlanda, Giovanni ^a,b   Flex, Andrea ^a,b  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d School of Medicine   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPROTEGERIN;

AGED; ARTICLE; BRAIN ISCHEMIA; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TNFRSF11B GENE;

AGED; BASE SEQUENCE; CASE-CONTROL STUDIES; DIABETES COMPLICATIONS; DNA; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; ITALY; MALE; OSTEOPROTEGERIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE;

EID: 84872283806     PISSN: 03406717     EISSN: 14321203     Source Type: Journal    
DOI: 10.1007/s00439-012-1224-9     Document Type: Article

References (37)

1. Avignon A, Sultan A, Piot C, Elaerts S, Cristol JP, Dupuy AM (2005) Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 28:2176-2180
2. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337-342
3. Browner WS, Lui LY, Cummings SR (2001) Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86:631-637
4. Bucay N, Sarosi I, Dunstan CR, Morony S et al (1998) Osteoprotegerin- deficient mice develop early-onset osteoporosis and arterial calcification. Genes Dev 2:1260-1268
5. Crisafulli A, Micari A, Altavilla D, Saporito F et al (2005) Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond) 109:389-395
6. Dai Y, Shen L (2007) Relationships between serum osteoprotegerin, matrix metalloproteinase-2 levels and bone metabolism in postmenopausal women. Chin Med J (Engl) 20:2017-2021
7. Dichgans M (2007) Genetics of ischaemic stroke. Lancet Neurol 6:149-161
8. Domingues-Montanari S, Mendioroz M, del Rio-Espinola A, Fernández-Cadenas I, Montaner J (2008) Genetics of stroke: a review of recent advances. Expert Rev Mol Diagn 8:495-513
9. Elkind MS (2010) Inflammatory mechanisms of stroke. Stroke 41:S3-S8
10. Golledge J, McCann M, Mangan S, Lam A, Karan M (2004) Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 35:1636-1641
11. Goranova-Marinova V, Goranov S, Pavlov P, Tzvetkova T (2007) Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations. Haematologica 92:1000-1001
12. Guldiken B, Guldiken S, Turgut B, Turgut N, Demir M, Celik Y, Arikan E, Tugrul A (2007) Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct. Thromb Res 120:511-516
13. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685-1695
14. Hassan A, Markus HS (2000) Genetics and ischaemic stroke. Brain 123:1784-1812
15. Jensen JK, Ueland T, Atar D, Gullestad L, Mickley H, Aukrust P, Januzzi JL (2010) Osteoprotegerin concentrations and prognosis in acute ischaemic stroke. J Intern Med 267:410-417
16. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y (2002) Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106:1192-1194
17. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J (2004) Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109:2175-2180
18. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135-1143
19. Lieb W, Gona P, Larson MG, Massaro JM et al (2010) Biomarkers of the osteoprotegerin pathway. Clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 30:1849-1854
20. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192:463-474
21. Mosheimer BA, Kaneider NC, Feistritzer C et al (2005) Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab 90:2964-2971
22. Oh ES, Rhee EJ, Oh KW, Lee WY, Baek KH, Yoon KH, Kang MI, Yun EJ, Park CY, Choi MG, Yoo HJ, Park SW (2005) Circulating osteoprotegerin levels are associated with age, waist- to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. Metabolism 54:49-54
23. Petrovic D, Milanez T, Kobal J, Bregar D, Potisk KP, Peterlin B (2003) Prothrombotic gene polymorphisms and atherothrombotic cerebral infarction. Acta Neurol Scand 108:109-113
24. Pitocco D, Zelano G, Gioffrè G, Di Stasio E, Zaccardi F, Martini F, Musella T, Scavone G, Galli M, Caputo S, Mancini L, Ghirlanda G (2009) Association between osteoprotegerin G1181C and T245G polymorphisms and diabetic charcot neuroarthropathy: a case-control study. Diabetes Care 32:1694-1697
25. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340:115-126
26. Sandberg WJ, Yndestad A, Øie E, Smith C, Ueland T, Ovchinnikova O, Robertson AK et al (2006) Enhanced T cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 26:857-863
27. Santl Letonja M, Letonja M, Nikolajević-Starcević JN, Petrovic D (2012) Association of manganese superoxide dismutase and glutathione S-transferases genotypes with carotid atherosclerosis in patients with diabetes mellitus type 2. Int Angiol 31:33-41
28. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC (2003) Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 88:1024-1028
29. Simonet WS, Lacey DL, Dunstan CR, Kelley M et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
30. Soufi M, Schoppet M, Sattler AM, Herzum M, Maisch B, Hofbauer LC, Schaefer JR (2004) Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab 89:3764-3768
31. Straface G, Biscetti F, Pitocco D, Bertoletti G, Misuraca M, Vincenzoni C, Snider F, Arena V, Stigliano E, Angelini F, Iuliano L, Boccia S, de Waure C, Giacchi F, Ghirlanda G, Flex A (2011) Assessment of the genetic effects of polymorphisms in the osteoprotegerin gene, TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability. Stroke 42:3022-3028
32. Turk N, Cukovic-Cavka S, Korsic M, Turk Z, Vucelic B (2009) Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn's disease. Eur J Gastroenterol Hepatol 21:159-166
33. Tuttolomondo A, Di Raimondo D, Forte GI, Casuccio A, Vaccarino L, Scola L, Pecoraro R, Serio A, Clemente G, Arnao V, Palmeri G, Misiano G, Lio D, Pinto A, Licata G (2012) Single nucleotide polymorphisms (SNPs) of pro-inflammatory/anti-inflammatory and thrombotic/fibrinolytic genes in patients with acute ischemic stroke in relation to TOAST subtype. Cytokine. 58(3):398-405
34. Ueland T, Yndestad A, Oie E, Florholmen G, Halvorsen B, Frøland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P (2005) Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 111:2461-2468
35. Whyte MP (2006) Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling. Ann NY Acad Sci 1068:143-164
36. Zhang J, Fu M, Myles D, Zhu X, Du J, Cao X, Chen YE (2002) PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 521:180-184
37. Ziegler S, Kudlacek S, Luger A, Minar E (2005) Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 182:175-180